Completed PHASE1 INTERVENTIONAL 4-arm NCT02218034

Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris

Sponsor: Allergan

Interventions AGN-190168 Formulation 1 AGN-190168 Formulation 2 tazarotene cream 0.1% tazarotene gel 0.1%

Updated 6 times since 2017 Last updated: Apr 28, 2015 Started: Aug 31, 2014 Primary completion: Mar 31, 2015 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02218034, this PHASE1 trial focuses on Acne Vulgaris and remains completed. Sponsored by Allergan, it has been updated 6 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• College Station, United States